Rubicon Research Q2 FY26: consolidated revenue up 39%, PAT up 56% YoY

Revenue growth above 20%Profit growth above 25%Results View source PDF Explain this filing

RUBICON · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+8.6%Reaction day

₹655.00

prior close

₹675.95

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-0.1%+8.7% vs market

Pharmaceuticals peers, median of 157sector+0.0%+8.6% vs sector

On the reaction day the stock moved 8.7 pts more than Nifty Microcap 250 and 8.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.2

10m

-0.9

15m

-0.7

30m

+1.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+8.6-0.1+8.7+0.0+8.6

Next day

+14.4+0.5+13.8-0.1+14.5

+10.4-0.3+10.7-0.9+11.3

+6.1-0.5+6.6-1.4+7.5

+6.0-0.8+6.7-1.6+7.5

+3.4-2.3+5.7-2.3+5.6

-0.2-2.8+2.6-3.1+2.9

15d

-3.1-4.9+1.8-3.6+0.5

-2.5-4.7+2.2-4.4+1.8

+4.1-7.7+11.9-5.7+9.8

+20.6-7.8+28.4-10.7+31.3

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Rubicon Research, listed Oct 16, 2025 after a Rs 13,775 mn IPO, posted Q2 FY26 standalone revenue of Rs 3,364.67 mn, up 32% YoY. Standalone PAT rose 6.8% to Rs 458.12 mn. Consolidated revenue grew 39% to Rs 4,120.18 mn and PAT rose 56% to Rs 538.53 mn. For H1 FY26, consolidated revenue grew 24.8% to Rs 7,645.12 mn and PAT rose 62% to Rs 971.53 mn. First quarterly results since listing. Deloitte issued an unqualified limited review.

Likely market impact

Strong consolidated earnings growth and clean audit review mark a positive start for shareholders post the October 2025 listing.